211 related articles for article (PubMed ID: 30859654)
1. Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans.
Bedolla RG; Shah DP; Huang SB; Reddick RL; Ghosh R; Kumar AP
Mol Carcinog; 2019 Jun; 58(6):854-861. PubMed ID: 30859654
[TBL] [Abstract][Full Text] [Related]
2. Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.
Batth IS; Yun H; Kumar AP
Mol Carcinog; 2015 Oct; 54(10):937-46. PubMed ID: 26152593
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.
Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Saad F; Chun FK; Shariat SF; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Int J Urol; 2018 Nov; 25(11):929-936. PubMed ID: 30146729
[TBL] [Abstract][Full Text] [Related]
4. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
6. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians.
Shiina M; Hashimoto Y; Kato T; Yamamura S; Tanaka Y; Majid S; Saini S; Varahram S; Kulkarni P; Dasgupta P; Mitsui Y; Sumida M; Tabatabai L; Deng G; Kumar D; Dahiya R
Oncotarget; 2017 Jan; 8(5):8356-8368. PubMed ID: 28039468
[TBL] [Abstract][Full Text] [Related]
9. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
10. Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.
Yoon TM; Kim SA; Park YL; Lee KH; Sung MW; Lee JK; Lim SC; Chung IJ; Joo YE
Head Neck; 2013 Aug; 35(8):1106-13. PubMed ID: 22887469
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence.
Bedolla RG; Gong J; Prihoda TJ; Yeh IT; Thompson IM; Ghosh R; Kumar AP
PLoS One; 2012; 7(9):e44917. PubMed ID: 23028678
[TBL] [Abstract][Full Text] [Related]
12. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
[TBL] [Abstract][Full Text] [Related]
13. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
[TBL] [Abstract][Full Text] [Related]
14. Racial disparity of epidermal growth factor receptor expression in prostate cancer.
Shuch B; Mikhail M; Satagopan J; Lee P; Yee H; Chang C; Cordon-Cardo C; Taneja SS; Osman I
J Clin Oncol; 2004 Dec; 22(23):4725-9. PubMed ID: 15570072
[TBL] [Abstract][Full Text] [Related]
15. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.
Platz EA; Rimm EB; Willett WC; Kantoff PW; Giovannucci E
J Natl Cancer Inst; 2000 Dec; 92(24):2009-17. PubMed ID: 11121463
[TBL] [Abstract][Full Text] [Related]
16. The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.
Duan X; Xu X; Yin B; Hong B; Liu W; Liu Q; Tao Z
J Clin Lab Anal; 2019 Jun; 33(5):e22871. PubMed ID: 30958616
[TBL] [Abstract][Full Text] [Related]
17. RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma.
Kim SA; Yoon TM; Lee DH; Park YL; Lee KH; Lim SC; Joo YE; Lee JK
Auris Nasus Larynx; 2014 Apr; 41(2):201-6. PubMed ID: 24287326
[TBL] [Abstract][Full Text] [Related]
18. Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells.
Yu Q; Wang J; Li T; Guo X; Ding S; Che X; Zhu L; Peng Y; Xu X; Zou G; Zhang X
J Cell Mol Med; 2021 Feb; 25(3):1601-1612. PubMed ID: 33410267
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor mutations and polymorphisms in African American prostate cancer.
Koochekpour S; Buckles E; Shourideh M; Hu S; Chandra D; Zabaleta J; Attwood K
Int J Biol Sci; 2014; 10(6):643-51. PubMed ID: 24948877
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
